Amyotrophic lateral sclerosis – The tools of the trait
Identifieur interne : 001120 ( Main/Exploration ); précédent : 001119; suivant : 001121Amyotrophic lateral sclerosis – The tools of the trait
Auteurs : Carsten W. Lederer [Chypre (pays)] ; Niovi Santama [Chypre (pays)]Source :
- Biotechnology Journal [ 1860-6768 ] ; 2007-05.
English descriptors
Abstract
The aim of this review is to analyze how our knowledge on the etiology, pathology, and treatment of amyotrophic lateral sclerosis (ALS) has profited from the application of biotechnology tools for the identification of disease markers, the development of animal disease models, and the design of innovative therapeutics. In humans, ALS‐specific clinical, genetic or protein biomarkers, or panels of biomarkers stemming from genomics and proteomics analyses can be critical for early diagnosis, monitoring of disease progression, drug validation in clinical trials, and identification of therapeutic targets for subsequent drug development. At the same time, animal models representing a number of human superoxide dismutase 1 mutations, intermediate‐filament disorganization or axonal‐transport defects have been invaluable in unraveling aspects of the pathophysiology of the disease; in each case, these only represent a small proportion of all ALS patients. Preclinical and clinical trials, although at present heavily concentrating on pharmacological approaches, are embracing the emerging alternative strategies of stem‐cell and gene therapy. In combination with a further subcategorization of patients and the development of corresponding model systems for functional analyses, they will significantly influence the already changing face of ALS therapy.
Url:
DOI: 10.1002/biot.200600247
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Amyotrophic lateral sclerosis – The tools of the trait</title><author><name sortKey="Lederer, Carsten W" sort="Lederer, Carsten W" uniqKey="Lederer C" first="Carsten W." last="Lederer">Carsten W. Lederer</name></author><author><name sortKey="Santama, Niovi" sort="Santama, Niovi" uniqKey="Santama N" first="Niovi" last="Santama">Niovi Santama</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2F15259809724AF8FC51AE652AD1E80CCEFA92F7</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/biot.200600247</idno><idno type="url">https://api.istex.fr/document/2F15259809724AF8FC51AE652AD1E80CCEFA92F7/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002E55</idno><idno type="wicri:Area/Main/Curation">002A72</idno><idno type="wicri:Area/Main/Exploration">001120</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Amyotrophic lateral sclerosis – The tools of the trait</title><author><name sortKey="Lederer, Carsten W" sort="Lederer, Carsten W" uniqKey="Lederer C" first="Carsten W." last="Lederer">Carsten W. Lederer</name><affiliation wicri:level="1"><country xml:lang="fr">Chypre (pays)</country><wicri:regionArea>Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, Nicosia</wicri:regionArea><wicri:noRegion>Nicosia</wicri:noRegion></affiliation></author><author><name sortKey="Santama, Niovi" sort="Santama, Niovi" uniqKey="Santama N" first="Niovi" last="Santama">Niovi Santama</name><affiliation wicri:level="1"><country xml:lang="fr">Chypre (pays)</country><wicri:regionArea>Department of Biological Sciences, University of Cyprus and Cyprus Institute of Neurology and Genetics, Nicosia</wicri:regionArea><wicri:noRegion>Nicosia</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Biotechnology Journal</title><title level="j" type="sub">Healthcare Nutrition Technology</title><title level="j" type="abbrev">Biotechnology Journal</title><idno type="ISSN">1860-6768</idno><idno type="eISSN">1860-7314</idno><imprint><publisher>WILEY‐VCH Verlag</publisher><pubPlace>Weinheim</pubPlace><date type="published" when="2007-05">2007-05</date><biblScope unit="volume">2</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="608">608</biblScope><biblScope unit="page" to="621">621</biblScope></imprint><idno type="ISSN">1860-6768</idno></series><idno type="istex">2F15259809724AF8FC51AE652AD1E80CCEFA92F7</idno><idno type="DOI">10.1002/biot.200600247</idno><idno type="ArticleID">BIOT200600247</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1860-6768</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amyotrophic lateral sclerosis</term><term>Motor neuron disease</term><term>Neurodegeneration</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this review is to analyze how our knowledge on the etiology, pathology, and treatment of amyotrophic lateral sclerosis (ALS) has profited from the application of biotechnology tools for the identification of disease markers, the development of animal disease models, and the design of innovative therapeutics. In humans, ALS‐specific clinical, genetic or protein biomarkers, or panels of biomarkers stemming from genomics and proteomics analyses can be critical for early diagnosis, monitoring of disease progression, drug validation in clinical trials, and identification of therapeutic targets for subsequent drug development. At the same time, animal models representing a number of human superoxide dismutase 1 mutations, intermediate‐filament disorganization or axonal‐transport defects have been invaluable in unraveling aspects of the pathophysiology of the disease; in each case, these only represent a small proportion of all ALS patients. Preclinical and clinical trials, although at present heavily concentrating on pharmacological approaches, are embracing the emerging alternative strategies of stem‐cell and gene therapy. In combination with a further subcategorization of patients and the development of corresponding model systems for functional analyses, they will significantly influence the already changing face of ALS therapy.</div></front></TEI><affiliations><list><country><li>Chypre (pays)</li></country></list><tree><country name="Chypre (pays)"><noRegion><name sortKey="Lederer, Carsten W" sort="Lederer, Carsten W" uniqKey="Lederer C" first="Carsten W." last="Lederer">Carsten W. Lederer</name></noRegion><name sortKey="Santama, Niovi" sort="Santama, Niovi" uniqKey="Santama N" first="Niovi" last="Santama">Niovi Santama</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001120 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001120 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2F15259809724AF8FC51AE652AD1E80CCEFA92F7
|texte= Amyotrophic lateral sclerosis – The tools of the trait
}}
| This area was generated with Dilib version V0.6.23. |  |